Design and Drug Screening of Targeted Proteins Inhibitor
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 1396
Special Issue Editors
Interests: structure-based drug design; protein inhibitor; antibacterial activity; antifungal activity; insecticidal activity; anti-inflammatory
Special Issue Information
Dear Colleagues,
In the drug discovery process, the development of novel drugs with potential interactions with therapeutic protein targets is of central importance. However, it is well-known that bringing a new drug into the market is a costly process in terms of money, manpower, and time. Thus, it is important to overcome limitations of the conventional drug discovery methods with efficient, low-cost, and broad-spectrum computational alternatives. To this end, the employment of rational drug design techniques by top pharmaceutical companies and other research groups has become essential for the preliminary stage of drug discovery to expedite the drug development process in a more cost-efficient way and to minimize failures in the final stage.
In the entire drug discovery paradigm, lots of different design strategies are employed. For example, the combination of two different bioactive units to generate a single bioactive scaffold (molecular hybridization) is a popular design strategy for medicinal chemists and is also known as scaffold hopping strategy. Structure-based drug design (SBDD) is a more specific, efficient, and rapid process for lead discovery and optimization because it deals with the 3D structure of a target protein and knowledge about the disease at the molecular level. Current SBDD methods consider the key features of the binding cavity of the therapeutic target to design efficient ligands. Computational resources serve as an efficient technology for accelerating the drug discovery process, which includes various screening procedures, combinatorial chemistry, and calculations of properties such as absorption, distribution, metabolism, excretion and toxicity (ADMET).
Dr. Ding Li
Dr. Zhigang Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rational drug design
- computer-aided drug discovery
- structure-based drug design
- fragment-based drug discovery
- ligand-based drug design
- bioisosterism
- scaffold hoping
